Bli medlem
Bli medlem

Du är här

2016-10-17

Recipharm AB: Recipharm to open new GLP bioanalysis laboratory in Sweden

Recipharm, the contract development and manufacturing organisation
(CDMO), has announced a 5 million SEK investment into a new GLP (Good
Laboratory Practice) compliant bioanalysis laboratory at its
development facility in Uppsala, Sweden, in response to growing
customer demand.

The investment will see the opening of a 500 square metre
purpose-built facility in November 2016, which will become the
largest GLP bioanalysis laboratory of its kind in the Nordic
countries.

Recipharm's development team in Uppsala specialises in medicinal
chemistry, offering synthesis and analytical preclinical development
services to drug development companies progressing products through
clinical trials.

From its new laboratory, the CDMO will significantly increase its
capacity, with the capability to process more than 10,000 plasma
samples per week.

Commenting on the investment, Fredrik Lehmann, General Manager at
Recipharm Development in Uppsala said: "This is a strategic
investment for Recipharm as there is a real need for more GLP
bioanalysis laboratories in the Nordic region.

Bioanalysis requires specialist expertise and establishing the
necessary capabilities can be a costly investment, proving a barrier
to entry for many contract services providers. Having first started
out in a collaboration with a subcontractor, we are now delighted to
be able to expand our offering in-house to service an unmet need for
bioanalysis capabilities".

"The new laboratory will dramatically increase our capacity, allowing
us to continue to grow our European customer base and expand our
expert team of chemists," added Fredrik.

In order to support the increasing demand of bioanalysis services,
Recipharm Development in Uppsala plans to recruit several new PhD
level chemists in the coming months and aims to more than double its
team of 35 in the next couple of years.

Contact information
Fredrik Lehmann, General Manager, fredrik.lehmann@recipharm.com, +46
73 354 12 39

Carl-Johan Spak, Executive Vice President Global Technologies,
carl-johan.spak@recipharm.com,

+46 8 602 53 13
For media enquiries, please contact Lindsay Baldry at ramarketing:
lindsay@ramarketingpr.com, +44 (0)191 222 1242, ramarketingpr.com,
Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin:
/ramarketing

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 3,500
employees. Recipharm offers manufacturing services of pharmaceuticals
in various dosage forms, production of clinical trial material and
APIs, and pharmaceutical product development. Recipharm manufactures
several hundred different products to customers ranging from Big
Pharma to smaller research- and development companies. Recipharm's
turnover is approximately SEK 5.0 billion and the Company operates
development and manufacturing facilities in France, Germany, India,
Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is
headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is
listed on Nasdaq Stockholm.

For more information on Recipharm and its services, please visit
www.recipharm.com

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03

www.recipharm.com
-----------------------------------------------------------
http://news.cision.com/recipharm-ab/r/recipharm-to-open-new-glp-bioanaly...
http://mb.cision.com/Main/9273/2102104/575555.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.